Urovant Sciences announces FDA approval of GEMTESA®

Please see Important Safety Information and Full Product Information.

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.
Our goal is to be a leading specialty company, recognized and trusted by patients and providers for our commitment to urology.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients with urological conditions that are overlooked, misunderstood or not well managed.
Careers at Urovant Sciences offer exceptional possibilities.
When you join Urovant Sciences, you become part of our world-class team and dynamic culture where you have the opportunity to develop and grow, personally and professionally.
Careers CTA Image
In The News

February 12, 2021
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
February 11, 2021
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
December 23, 2020
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)